MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Patrick Neven et al.|Journal of Clinical Oncology|2017Cited by 1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerDavid Miles, Gilles Romieu, Arlene Chan et al.|Journal of Clinical Oncology|2010Cited by 887
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane TreatmentE. Donnall Thomas, Henri Roché, Henry Gómez et al.|Journal of Clinical Oncology|2007Cited by 483
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and CapecitabineEdith A. Perez, Gabriel N. Hortobágyi, Guillermo Lerzo et al.|Journal of Clinical Oncology|2007Cited by 392